Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 2, 2009, Pages 225-229

  Sewell, Justin L ^a   Stick, Kristine M ^b   Monto, Alexander ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Interferon; Ribavirin; Screening; Sustained virologic response

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; DOXORUBICIN; HEPATITIS B SURFACE ANTIBODY; PEGINTERFERON; REBETRON; RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ARTIFICIAL EMBOLISM; BLOOD LEVEL; CANCER GROWTH; CASE STUDY; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE DURATION; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK ASSESSMENT; UMBILICAL HERNIA; VIRUS LOAD; BIOPSY; CASE REPORT; COMPLICATION; FOLLOW UP; HEPATITIS C, CHRONIC; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; VIROLOGY;

ANTIVIRAL AGENTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 59149093374     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32831101b7     Document Type: Article

References (19)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
2. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34:593-602.
3. Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res 2003; 23:593-596.
4. Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Kobashi H, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004; 24:603-610.
5. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30:653-659.
6. Shindo M, Hamada K, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001; 33:1299-1302.
7. Takimoto M, Ohkoshi S, Ichida T, Takeda Y, Nomoto M, Asakura H, et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002; 47:170-176.
8. Tanaka H, Tsukuma H, Kasahara A. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87:741-749.
9. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131:174-181.
10. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36:S74-S83.
11. Sieja KS, Everson GT. De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci 2006; 51:600-602.
12. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12:5532-5535.
13. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-1417.
14. Poynard T, McHutchinson J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303-1313.
15. Kremer-Tal S, Narla G, Chen Y. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46:645-654.
16. Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C. A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC Cancer 2006; 6:278.
17. Miyagawa K, Sakakura C, Nakashima S, Yoshikawa T, Kin S, Nakase Y, et al. Down-regulation of RUNX1, RUNX3, and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res 2006; 26:3633-3643.
18. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31:339-346.
19. Gordon SC. Occult viral hepatitis and noncirrhotic hepatocellular carcinoma. Am J Gastroenterol 2005; 100:1745-1747.